A new study led by researchers at the UNC School of Medicine and Cartesian Therapeutics, found that immunotherapy can help ...
Although rheumatologists consider chimeric antigen receptor T-cell therapy “potentially transformative,” nearly 70% remain ...
The US Food and Drug Administration’s (FDA) guidance documents offer sponsors greater clarity on trial designs and control strategies that could potentially accelerate the development of in vivo CAR-T ...
A first clinical study suggests allogeneic CD19-targeted CAR-T cell therapy can safely induce durable remission in patients ...
While the use of radiation bridging therapy (BT) in chimeric antigen receptor (CAR) T-cell therapy for blood cancer is expanding, plenty of unanswered questions remain on topics such as ideal timing ...
FDA approval criteria primarily dictate the sequencing of multiple myeloma therapies, often restricting bispecific antibodies to later treatment lines. Institutional practices vary in using CAR T-cell ...
Editing CAR T cells to produce inflammatory cytokines helps them enter solid tumors and promote cancer killing.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results